In contrast with the muted enthusiasm that greeted Amgen, Inc.’s announcement of Phase I data for the combination of its KRAS G12C inhibitor with immune-checkpoint inhibitors, early data for its bispecific antibody tarlatamab in lung cancer generated much more excitement, and the company indicated it may expand the new drug’s reach as well.
Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC
The company presented data for its bispecific antibody tarlatamab at WCLC, drawing noticeably more excitement than highly anticipated but disappointing data for Lumakras with checkpoint inhibitors.
